PURPOSE: Type I pleuropulmonary blastoma (PPB) is a rare, cystic lung neoplasm in infants characterized by subtle malignant changes and a good prognosis. Recurrences after type I PPB are usually advanced type II or type III neoplasms with a poor prognosis. This article describes the first collection of type I PPB cases, analyzes outcome based on treatments of surgery or surgery plus chemotherapy, and presents type I PPB management recommendations. PATIENTS AND METHODS: Type I PPB cases from the International PPB Registry and literature were evaluated using standard statistical methods for outcomes based on age at diagnosis, sex, thoracic side, surgical extent, length of follow-up, constitutional/familial disease, pre-existing lung cysts, intrathoracic findings, and treatments (surgery or surgery and chemotherapy). RESULTS: Thirty-eight type I PPB cases were identified: Registry (n = 30) and literature (n = 8). Twenty children had surgery alone; eight (40%) experienced recurrence; and four died. Eighteen children had surgery and adjuvant chemotherapy; one experienced recurrence and died. All recurrences were type II or III PPB. Recurrence-free survival was higher in the surgery + chemotherapy group (P = .01); overall survival did not differ (P = .18). The improved recurrence-free survival was found only in males. Four of nine children with recurrence survived. CONCLUSION: Adjuvant chemotherapy appears to benefit type I PPB patients. Benefit limited to males requires broader substantiation. Salvage after types II and III recurrence is poor (four of nine; 44%). A rigorous surveillance schedule after type I PPB diagnosis might detect early recurrence and be an acceptable alternative to adjuvant chemotherapy.
PURPOSE:Type I pleuropulmonary blastoma (PPB) is a rare, cystic lung neoplasm in infants characterized by subtle malignant changes and a good prognosis. Recurrences after type I PPB are usually advanced type II or type III neoplasms with a poor prognosis. This article describes the first collection of type I PPB cases, analyzes outcome based on treatments of surgery or surgery plus chemotherapy, and presents type I PPB management recommendations. PATIENTS AND METHODS: Type I PPB cases from the International PPB Registry and literature were evaluated using standard statistical methods for outcomes based on age at diagnosis, sex, thoracic side, surgical extent, length of follow-up, constitutional/familial disease, pre-existing lung cysts, intrathoracic findings, and treatments (surgery or surgery and chemotherapy). RESULTS: Thirty-eight type I PPB cases were identified: Registry (n = 30) and literature (n = 8). Twenty children had surgery alone; eight (40%) experienced recurrence; and four died. Eighteen children had surgery and adjuvant chemotherapy; one experienced recurrence and died. All recurrences were type II or III PPB. Recurrence-free survival was higher in the surgery + chemotherapy group (P = .01); overall survival did not differ (P = .18). The improved recurrence-free survival was found only in males. Four of nine children with recurrence survived. CONCLUSION: Adjuvant chemotherapy appears to benefit type I PPB patients. Benefit limited to males requires broader substantiation. Salvage after types II and III recurrence is poor (four of nine; 44%). A rigorous surveillance schedule after type I PPB diagnosis might detect early recurrence and be an acceptable alternative to adjuvant chemotherapy.
Authors: Douglas R Stewart; Yoav Messinger; Gretchen M Williams; Jiandong Yang; Amanda Field; Kris Ann P Schultz; Laura A Harney; Leslie A Doros; Louis P Dehner; D Ashley Hill Journal: Hum Genet Date: 2014-08-14 Impact factor: 4.132
Authors: Kris Ann Schultz; Jiandong Yang; Leslie Doros; Gretchen M Williams; Anne Harris; Douglas R Stewart; Yoav Messinger; Amanda Field; Louis P Dehner; D Ashley Hill Journal: Pathol Case Rev Date: 2014-03
Authors: Purnima K Wagh; Margaret A Gardner; Xiaolan Ma; Melissa Callahan; John M Shannon; Susan E Wert; Yoav H Messinger; Louis P Dehner; D Ashley Hill; Kathryn A Wikenheiser-Brokamp Journal: J Pathol Date: 2015-01-20 Impact factor: 7.996
Authors: Stephan L Waelti; Laurent Garel; Dorothée Dal Soglio; Françoise Rypens; Michael Messerli; Josée Dubois Journal: Pediatr Radiol Date: 2017-09-07
Authors: Yoav H Messinger; Douglas R Stewart; John R Priest; Gretchen M Williams; Anne K Harris; Kris Ann P Schultz; Jiandong Yang; Leslie Doros; Philip S Rosenberg; D Ashley Hill; Louis P Dehner Journal: Cancer Date: 2014-09-10 Impact factor: 6.860
Authors: Zahra Alipour; Kris Ann P Schultz; Ling Chen; Anne K Harris; Ivan A Gonzalez; John Pfeifer; D Ashley Hill; Mai He; Louis P Dehner Journal: Pediatr Dev Pathol Date: 2021-07-15